The COVID-19 pandemic highlighted both the strengths and weaknesses of pharmaceutical supply chains.

In this article for peer-reviewed Journal of Clinical Studies, Rey Roman, Marken’s Senior Director of Regulatory Compliance, discusses the lessons learned from the disruption the pandemic caused to trade, distribution, logistics and quality, and how that led to a stronger clinical supply chain.